Low level of plasminogen increases risk for mortality in COVID-19 patients.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
05 08 2021
Historique:
received: 08 07 2021
accepted: 27 07 2021
revised: 26 07 2021
entrez: 6 8 2021
pubmed: 7 8 2021
medline: 12 8 2021
Statut: epublish

Résumé

The pathophysiology of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and especially of its complications is still not fully understood. In fact, a very high number of patients with COVID-19 die because of thromboembolic causes. A role of plasminogen, as precursor of fibrinolysis, has been hypothesized. In this study, we aimed to investigate the association between plasminogen levels and COVID-19-related outcomes in a population of 55 infected Caucasian patients (mean age: 69.8 ± 14.3, 41.8% female). Low levels of plasminogen were significantly associated with inflammatory markers (CRP, PCT, and IL-6), markers of coagulation (D-dimer, INR, and APTT), and markers of organ dysfunctions (high fasting blood glucose and decrease in the glomerular filtration rate). A multidimensional analysis model, including the correlation of the expression of coagulation with inflammatory parameters, indicated that plasminogen tended to cluster together with IL-6, hence suggesting a common pathway of activation during disease's complication. Moreover, low levels of plasminogen strongly correlated with mortality in COVID-19 patients even after multiple adjustments for presence of confounding. These data suggest that plasminogen may play a pivotal role in controlling the complex mechanisms beyond the COVID-19 complications, and may be useful both as biomarker for prognosis and for therapeutic target against this extremely aggressive infection.

Identifiants

pubmed: 34354045
doi: 10.1038/s41419-021-04070-3
pii: 10.1038/s41419-021-04070-3
pmc: PMC8340078
doi:

Substances chimiques

Biomarkers 0
Inflammation Mediators 0
Plasminogen 9001-91-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

773

Informations de copyright

© 2021. The Author(s).

Références

Cell Death Differ. 2020 Feb;27(2):405-419
pubmed: 31907390
QJM. 2020 Aug 1;113(8):539-545
pubmed: 32275753
Biochemistry. 2009 Jan 20;48(2):242-53
pubmed: 19140693
Emerg Med J. 2021 May 21;:
pubmed: 34021028
Int J Immunopathol Pharmacol. 2005 Jan-Mar;18(1):95-112
pubmed: 15698515
Cell Death Dis. 2020 Jun 8;11(6):438
pubmed: 32513951
Cell Death Dis. 2020 Jun 8;11(6):429
pubmed: 32513989
Cell Death Differ. 2020 Feb;27(2):829-830
pubmed: 31900426
Biol Direct. 2020 Oct 9;15(1):17
pubmed: 33036642
Cell Death Dis. 2020 Aug 19;11(8):656
pubmed: 32814759
Biomark Insights. 2021 May 24;16:11772719211013363
pubmed: 34103886
Cell Death Dis. 2020 Oct 27;11(10):921
pubmed: 33110074
J Thromb Haemost. 2015 Jun;13 Suppl 1:S98-105
pubmed: 26149056
PLoS One. 2014 Mar 06;9(6):e90764
pubmed: 24603559
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Biochem Biophys Res Commun. 2007 Jun 22;358(1):277-84
pubmed: 17482573
Cell Death Discov. 2020 Oct 10;6:101
pubmed: 33072409
Cell Death Differ. 2020 Mar;27(3):843-857
pubmed: 31836831
Biol Direct. 2020 Nov 2;15(1):21
pubmed: 33138856
Semin Thromb Hemost. 2020 Oct;46(7):859-862
pubmed: 32882718
Cell Death Differ. 2020 Mar;27(3):831-832
pubmed: 32034315
FEBS J. 2012 Jan;279(1):154-67
pubmed: 22035263
Cell Death Differ. 2020 May;27(5):1457-1474
pubmed: 32231246
Cell Death Differ. 2020 Mar;27(3):999-1007
pubmed: 31332296
Biol Direct. 2020 Jun 15;15(1):10
pubmed: 32539851
Biol Direct. 2020 Oct 14;15(1):18
pubmed: 33054808
Cell Death Differ. 2020 Jun;27(6):1807-1818
pubmed: 31796886
Biol Direct. 2020 Dec 29;15(1):30
pubmed: 33371901
Cell Death Discov. 2020 May 26;6:38
pubmed: 32501411
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1684-1707
pubmed: 33629339
Biol Direct. 2019 Aug 23;14(1):16
pubmed: 31443736
Biol Direct. 2020 Nov 27;15(1):28
pubmed: 33246479
J Am Coll Surg. 2020 Aug;231(2):203-204
pubmed: 32593497
Cell Death Differ. 2021 Apr 20;:
pubmed: 33879858
Cell Death Discov. 2020 Nov 25;6:130
pubmed: 33251029
Arch Biochem Biophys. 2000 Jan 15;373(2):435-41
pubmed: 10620369
BMJ. 2020 Oct 23;371:m3862
pubmed: 33097561
Cell Death Differ. 2020 Nov;27(11):3196-3207
pubmed: 32514047
Cell Death Differ. 2020 May;27(5):1740-1742
pubmed: 32203169
Science. 2020 May 29;368(6494):1012-1015
pubmed: 32303590
Cell Death Differ. 2020 Dec;27(12):3209-3225
pubmed: 33037393
Cell Death Differ. 2020 Aug;27(8):2517-2530
pubmed: 32127658
Biol Direct. 2020 Feb 13;15(1):3
pubmed: 32054490
Physiol Rev. 2020 Jul 1;100(3):1065-1075
pubmed: 32216698
Biol Direct. 2019 Nov 21;14(1):22
pubmed: 31752974
Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22351-22356
pubmed: 32826331
Sci Rep. 2021 Jan 15;11(1):1580
pubmed: 33452298
Drug Discov Today. 2020 Aug;25(8):1528-1534
pubmed: 32562843
Haemostasis. 1988;18 Suppl 1:61-8
pubmed: 3127309
Cell Death Dis. 2020 Jul 8;11(7):512
pubmed: 32641681
Cell Death Dis. 2020 Dec 8;11(12):1042
pubmed: 33293527
Biol Direct. 2020 Oct 16;15(1):19
pubmed: 33066821
J Autoimmun. 2021 Jan;116:102560
pubmed: 33139116
Biol Direct. 2019 Apr 29;14(1):8
pubmed: 31036036
Cell Death Discov. 2020 Nov 27;6:134
pubmed: 33262894
Cell Death Dis. 2020 Jul 8;11(7):516
pubmed: 32641762
Cell Cycle. 2012 Oct 1;11(19):3638-48
pubmed: 22935697
Biochem J. 1997 Feb 15;322 ( Pt 1):229-34
pubmed: 9078266
Cell Cycle. 2010 Sep 15;9(18):3730-9
pubmed: 20855944
Clin Microbiol Infect. 2020 Jul;26(7):842-847
pubmed: 32344166
J Thromb Haemost. 2020 Sep;18(9):2118-2122
pubmed: 32543119
Cell Death Differ. 2020 May;27(5):1451-1454
pubmed: 32205856

Auteurs

David Della-Morte (D)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. david.dellamorte@uniroma2.it.
Department of Neurology, Evelyn F. McKnight Brain Institute, Miller School of Medicine, University of Miami, Miami, FL, USA. david.dellamorte@uniroma2.it.
Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Rome, Italy. david.dellamorte@uniroma2.it.
Interdisciplinary Center for Advanced Studies on Lab-on-Chip and Organ-on-Chip Applications (ICLOC), University of Rome Tor Vergata, Rome, Italy. david.dellamorte@uniroma2.it.

Francesca Pacifici (F)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Camillo Ricordi (C)

Diabetes Research Institute, Cell Transplant Center, Miller School of Medicine, University of Miami, Miami, FL, USA.

Renato Massoud (R)

Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.

Valentina Rovella (V)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Department of Medical Sciences, Fondazione Policlinico Tor Vergata, Rome, Italy.

Stefania Proietti (S)

Clinical and Molecular Epidemiology, IRCCS San Raffaele Roma, Rome, Italy.

Mariannina Iozzo (M)

Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.

Davide Lauro (D)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Department of Medical Sciences, Fondazione Policlinico Tor Vergata, Rome, Italy.

Sergio Bernardini (S)

Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.

Stefano Bonassi (S)

Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Rome, Italy.
Clinical and Molecular Epidemiology, IRCCS San Raffaele Roma, Rome, Italy.

Nicola Di Daniele (N)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Department of Medical Sciences, Fondazione Policlinico Tor Vergata, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH